Oral Terbinafine for Tinea Pedis
For tinea pedis in adults, prescribe oral terbinafine 250 mg once daily for 1-2 weeks, which achieves mycological cure rates of 72-86% and offers faster clinical resolution than topical alternatives. 1
Dosing Regimen
Standard dosing: Terbinafine 250 mg orally once daily for 1-2 weeks is the evidence-based regimen 1. The guideline evidence demonstrates:
- 1 week of treatment achieves similar mycological cure rates (72% at week 4) compared to 4 weeks of topical clotrimazole, but with faster clinical symptom resolution 1
- 2 weeks of treatment shows 86% mycological cure rates and may have slightly lower relapse rates compared to itraconazole 1
The medication can be taken with or without food 2.
When to Use Oral vs Topical Therapy
Oral terbinafine should be reserved for:
- Severe or extensive disease
- Failed topical antifungal therapy
- Hyperkeratotic (moccasin-type) tinea pedis
- Concomitant onychomycosis
- Immunocompromised patients 3
For localized interdigital tinea pedis, topical therapy remains first-line.
Required Monitoring
Baseline testing is mandatory 2:
- Serum transaminases (ALT and AST) before initiating treatment
- Complete blood count (CBC) in patients with history of hepatotoxicity or hematological abnormalities
No routine monitoring during the short 1-2 week course is typically needed for otherwise healthy adults, given the brief treatment duration.
Critical Safety Warnings
The FDA label highlights serious risks that require patient counseling 2:
Hepatotoxicity: Liver failure leading to transplant or death has occurred. Discontinue immediately if signs develop (nausea, anorexia, fatigue, jaundice, dark urine, pale stools, right upper quadrant pain).
Taste disturbance: Can be severe, prolonged, or permanent. Occurs in >2% of patients. Discontinue if this develops 2.
Smell disturbance: May be prolonged or permanent. Discontinue if loss of smell occurs 2.
Neutropenia: Rare but serious. The guideline notes occasional isolated neutropenia as a concerning adverse event 1.
Depressive symptoms: Monitor for mood changes, worthlessness, sleep pattern changes, loss of energy 2.
Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome have been reported 2.
Contraindications
- History of allergic reaction to oral terbinafine (risk of anaphylaxis) 2
- Active or chronic liver disease 4
- Pregnancy (avoid initiating during pregnancy) 2
Common Pitfalls to Avoid
Duration error: While the FDA label indicates 12 weeks for toenail onychomycosis 2, this is NOT the regimen for tinea pedis. The guideline evidence clearly supports only 1-2 weeks for skin infections 1.
Failure to obtain baseline labs: This is explicitly recommended by the FDA and can have medicolegal implications if hepatotoxicity develops 2.
Not counseling about taste/smell changes: These can be permanent and patients must be warned before starting treatment 2.
Drug Interactions
Terbinafine inhibits CYP2D6 and has clinically significant interactions with 2:
- Desipramine
- Tricyclic antidepressants
- Beta-blockers metabolized by CYP2D6
- SSRIs (particularly those metabolized by CYP2D6)
Also interacts with caffeine, cyclosporine, rifampin, cimetidine, and fluconazole 2.
Comparative Efficacy
The guideline evidence demonstrates terbinafine's advantages 1:
- Similar mycological efficacy to itraconazole 100 mg for 2 weeks, but may have slightly lower relapse rates
- Faster clinical resolution than topical clotrimazole despite similar cure rates
- Once-daily dosing for briefer periods than topical treatments, improving compliance
Special Populations
Renal impairment: Use with caution; dose adjustment may be needed 2.
Breastfeeding: Terbinafine passes into breast milk and may harm the baby. Discuss risks/benefits 2.
Children: The guideline notes terbinafine is well tolerated in children, though baseline monitoring should be considered as it's not licensed for pediatric onychomycosis 1.